arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Sunday 1 July 2018

Sunday 01 Jul

08:00

Registration opens

08:00

General Assembly ISHAM

09:00

Plenary session: Presidential address

Arunaloke Chakrabarti, India

10:00

Break

10:30

Parallel session I

Parallel session I will take place from 10:30 hrs. until 12:00 hrs. and consists of six symposia.

S1.1 Basic mechanisms of antifungal immunity

Convener: Mihalis Lionakis, USA

10:30

S1.1a Basic mechanisms of antifungal immunity

Mihalis Lionakis, USA

10:55

S1.1b Protection and pathology in pulmonary aspergillosis

Luigina Romani, Italy

11:20

S1.1c Protective immune responses during cryptococcosis

Carolina Coelho, USA

11:45

S1.1d Evolution of Candida albicans colonization and anti-Candida innate and adaptive immunity in patients having undergone surgical resection for Crohn's disease

Daniel Poulain, France

S1.2 Mycoctic keratitis

Convener: Lalitha Prajna, India

10:30

S1.2a Update and epidemiology of mycotic infections of the eye

Lalitha Prajna, India

10:55

S1.2b Molecular characterization, diagnosis and antifungal susceptibility patterns of clinically relevant Fusarium species

Abdullah Al-Hatmi, the Netherlands

11:20

S1.2c Two Aspergillus species, A. flavus and A. fumigatus – a comparative study of their conidial surface properties and immunological reactivities

Vishukumar Aimanianda, France

11:45

S1.2d Fungal keratitis in The Netherlands

Claudy Oliveira dos Santos, the Netherlands

S1.3 The Mycobiome in Health and Disease

Convener: Mahmoud Ghannoum, USA

10:30

S1.3a Mycobiome and Bacteriome Interactions: vital key of health and disease

Mahmoud Ghannoum, USA

10:55

S1.3b Fungal feelings in the Irritable Bowel Syndrome 

René van den Wijngaard, the Netherlands

11:20

S1.3c The Mycobiota: Interactions between Commensal Fungi and the Host

David Underhill, USA

11:45

S1.3d Gastrointestinal microbiota alteration Induced by Mucor circinelloides in a murine model

Soo Chan Lee, USA

S1.4 Chromoblastomycosis: the role of immunity

Convener: Peiying Feng, China

10:30

S1.4a Development of immunomodulators as adjuvant in treatment of experimental chromoblastomycosis caused by Fonseca pedrosoi

Anamelia Lorenzetti Bocca, Brazil

10:55

S1.4b Transformation into muriform cells links to refractory murine chromoblastomycosis due to F. pedrosoi involving a chitin-induced impairment of IFN-gamma production

Bilin Dong, China

11:20

S1.4c MelLec: A new receptor for melanised fungi

Gordon D. Brown, United Kingdom

11:45

S1.4d Chromoblastomycosis and sporotrichosis in Madagascar: an update on epidemiology, clinical presentation and molecular diagnosis

Tahinamandranto Rasamoelina, Madagascar

S1.5 EFISG/ECMM Aspergillus guidelines

Conveners: Sevtap Arikan, Turkey & Oliver Cornely, Germany

10:30

S1.5a Guidance in times of antifungal resistance / Current perspective for antifungal resistance in aspergillosis

Paul Verweij, the Netherlands

10:55

S1.5b Chronic pulmonary aspergillosis – Focus on differences between EU and US guidelines / Clinical guidelines for chronic pulmonary aspergillosis

David Denning, United Kingdom

11:20

S1.5c Children are not small adults:  Management of invasive aspergillosis in pediatric patients

Andreas Groll, Germany

11:45

S1.5d How to properly diagnose invasive aspergillosis? / Recommendations on mycologic diagnosis of invasive aspergillosis

Cornelia Lass-Flörl, Austria

S1.6 ISHAM Working Group: Genotyping of Cryptococcus

Convener: Massimo Coliati, Italy

10:30

S1.6a Cryptococcus neoformans and C. gattii species complex genotypes in China

Xiao Meng, China

10:55

S1.6b Genotypes of Cryptococcus neoformans and C. gattii species complex in Europe

Massimo Cogliati, Italy

11:20

S1.6c Molecular epidemiology of Cryptococcus in South Africa

Serisha Naicker, South Africa

11:45

S1.6d Molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii in Latin America

Carolina Firacative, Colombia

12:00

Lunch break

12:15

Poster Pitch Session I

12:15 - 13:15 Ruby lounge (first floor)

12:30

Sponsored Symposium

Plenary room: Forum

13:30

Plenary session: WHO is afraid of fungus

Carmem da Silva, Switzerland

14:30

Break

15:00

Parallel session II

Parallel session II will take place from 15:00 hrs. until 16:30 hrs. and consists of six symposia.

S2.1 Nutrition and stress

Convener: Alistair Brown, United Kingdom

15:00

S2.1a Carbon metabolism, immune suppression, and virulence in Candida albicans

Slavena Vylkova, Germany

15:25

S2.1b Adaptation to complex host niches by fungal pathogen C. albicans drives resistance against neutrophil attack

Constantin Urban, Sweden

15:50

S2.1c Nutrient sensing and Cryptococcal virulence

James Kronstad, Canada

16:15

S2.1d Fungal Transformers: Tracking a Moving Target

Delma Childers, United Kingdom

S2.2 Candida auris

Convener: Ana Alastruey-Izquierdo, Spain

15:00

S2.2a Identification and antifungal susceptibility of Candida auris

Anuradha Chowdhary, India

15:25

S2.2b Management of Candida auris outbreaks at a national level

Silke Schelenz, United Kingdom

15:50

S2.2c Global Epidemiology and ‎strategies to control the emergence of a superbug

Tom Chiller, USA

16:15

S2.2d Skin and surface disinfection challenges for the emerging pathogen Candida auris

Ryan Kean, United Kingdom

S2.3 Antifungal stewardship

Convener: Martin Hoenigl, Austria

15:00

S2.3a Azole prophylaxis: Cost-effective strategies and money wasters

Jürgen Prattes, Austria

15:25

S2.3b Echinocandins in patients with hematologic malignancies: Indications, dosage, costs and outcome

Werner Heinz, Germany

15:50

S2.3c Emerging diagnostics for invasive mould infections and diagnostic-driven treatment strategies

Sophia Koo, USA

16:15

S2.3d Impact of infectious diseases consultation on mortality in patients with candidemia

Andrej Spec, USA

S2.4 Global epidemiology & One Health of Aspergillus fumigatus

Conveners: Paul Verweij, the Netherlands, Katrien Lagrou, Belgium

15:00

S2.4a Triazole resistance mechanisms in A. fumigatus:what do we learn from full genome sequencing

Matthew Fisher, United Kingdom

15:25

S2.4b Evolving epidemiology and spread of azole resistance in A. fumigatus

Eveline Snelders, the Netherlands

15:50

S2.4c Role of agricultural pesticide use in the evolution of triazole resistance in fungi

Bart Fraaije, United Kingdom

16:15

S2.4d Azole resistance in Aspergillus fumigatus: Screening in Cystic Fibrosis patients

Steffi Rocchi, France

S2.5 CLSI & EUCAST

Convener: Maiken Arendrup, Denmark

15:00

S2.5a Methods for mould testing for everyone or for special ones?

Joseph Meletiadis, Greece

15:25

S2.5b Absorbance, turbidity, diameter, Oh my!  Harmonizing disparate yeast testing methodologies

Shawn Lockhart, USA

15:50

S2.5c Susceptibility testing of dermatophytes, why and how?

Mahmoud Ghannoum, USA

16:15

S2.5d EUCAST susceptibility testing of Trichophyton rubrum: chloramphenicol and cycleheximide supplemented growth medium improve assay performance

Maiken Arendrup, Denmark

S2.6 ISHAM Working Group: Medical Phycology

Convener: Kochi Makimura, Japan

15:00

S2.6a Microsporidiosis and pythiosis in Medical Field

Kochi Makimura, Japan

15:25

S2.6b Genetic and biological insights from whole-genome sequencing of the pathogenic microalga Prototheca wickerhamii

Tomasz Jagielsk, Poland

15:50

S2.6c Prototheca infection in dogs and cats

Patrizia Danesi, Italy

16:15

S2.6d Characterization of CYP51 gene of pathogenic algae of Prototheca spp.

Michiaki Masuda, Japan

16:30

Parallelsession III

Parallel session III will take place from 16:30 hrs. until 17:00 hrs. and consists of six symposia.

S3.1 Evolutionary strategies of fungal pathogens

Convener: Eveline Snelders, the Netherlands

16:30

S3.1a Genome evolution in Candida albicans

Richard Bennet, USA

16:55

S3.1b Sexual reproduction and the evolution of eukaryotic microbial pathogens

Joseph Heitman, USA

17:20

S3.1c Understanding the role of the natural life history of Aspergillus fumigatus in azole resistance development

Bas Zwaan, the Netherlands

17:45

S3.1d Genome sequencing reveals infection mechanisms for two amphibian-infecting chytrid species

Rhys Farrer, United Kingdom

S3.2 AIDS-related mycoses

Convener: Darius Armstrong James, United Kingdom

16:30

S3.2a Immunity to fungal diseases in HIV

Claire Hoving, South Africa

16:55

S3.2b AIDS-related histoplasmosis in Latin America

Antoine Adenis, French Guyana

17:20

S3.2c AIDS-related mycoses in South East Asia

Thuy Le, Vietnam

17:45

S3.2d Talaromyces spp., new emerging pathogen in Jakarta, Indonesia: Analyses of clinical and animal isolates

Sem Samuel Surja, Indonesia

S3.3 Indoor fungi and sick buildings

Conveners: Jos Houbraken, the Netherlands & Irene Grant, USA

16:30

S3.3a Clinical Findings After Hazardous Indoor Microfungal Trichothecenes Mycotoxin Exposure: Disability outcomes risk analysis, immunosuppression and impaired genetic MTHFR detoxification status

Irene Grant, USA

16:55

S3.3b Chronic pain, indoor mold exposure, mycotoxin excretion, and response to antifungal therapy

James Dillard, USA

17:20

S3.3c Immunodeficiencies associated with indoor mold exposures and persistent illness, and available immune therapies

Irene Grant, USA

17:45

S3.3d Immunodeficiencies associated with indoor mold exposures and persistent illness, and available immune therapies

Sara Gago, United Kingdom

S3.4 ISHAM Working Group: Veterinary Mycology

Conveners: Amir Seyedmousavi, USA & Jacques Guillot, France

16:30

S3.4a Batrachochytrium salamandrivorans infections in amphibians

Ann Martel, Belgium

16:55

S3.4b Cryptic species, cats and aspergillosis

Vanessa Barrs, Australia

17:20

S3.4c Trichophyton benhamiae a zoonotic fungal pathogen

Vit Hubka, Czech Republic

17:45

3.4d The serial killer Saprolegnia – biofilm formation and combat strategies

Ida Skaar, Norway

S3.5 Pneumocystis

Convener: Alexandre Alanio, France

16:30

S3.5a Is Pneumocystis jirovecii a commensal of the respiratory tract of humans?

Sergio Vargas, Chile

16:55

S3.5b Pneumocystis species in mammals: how different are they?

Patrizia Danesi, Italy

17:20

S3.5c Pneumocystis jirovecii  detection in asymptomatic patients: what does its natural history tell us?

Alexandre Alanio, France

17:45

S3.5d Pneumocystis jirovecii colonization in pregnant women

Alejandra Calderón Hernández, Spain

18:00

Poster Pitch session II

19:00

ISHAM/ECMM/GAFFI meeting Eastern Europe (focusing on non ECMM member countries / countries with no active ECMM council delegate, including Ukraine, Poland, Bulgaria, Hungary, Slovakia, Albania, Bosnia, Croatia, Slovenia, Montenegro)

All ISHAM participants from the respective countries targeted by these outreach efforts would receive personal invitations to the respective evenings.

Sunday 01 Jul

Poster Pitch session I

Poster Terminal 1

12:15

PP1.001 - Azole-resistance in Aspergillus terreus and closely related species, an overseen problem?

Michaela Lackner, Austria

12:22

PP1.002 - Predominance of non-fumigatus Aspergillus species among patients suspected to pulmonary aspergillosis in a tropical and subtropical region

Hossein Zarrinfar, Iran

12:29

PP1.003 - Aspergillosis of the paranasal sinuses Report of 7 cases treated by Endoscopic Sinus Surgery (ESS)

Batool Sadeghi-Nejad, Iran

12:36

PP1.004 - Preliminary evaluation of a new immunochromatographic test for anti Aspergillus antibodies detection

Raphael Piarroux, France

12:43

PP1.006 - Molecular epidemiology and antifungal susceptibility profiles of Aspergillus terreus complex

Afsane Vaezi, Iran

12:50

PP1.007 - Identification and characterization of novel Aspergillus fumigatus mycoviruses

Jan Zoll, the Netherlands

12:57

PP1.008 - Molecular epidemiology and antifungal susceptibility of Aspergillus species isolated from asthma patients

Mohammad Hedayati, Iran

Poster Terminal 2

12:15

PP1.041 - Allergic bronchopulmonary aspergillosis presenting with lung mass-Report of six cases

Muhammad Irfan, Pakistan

12:22

PP1.042 - Galactomannan antigen as a diagnostic and prognostic marker in ICU subpopulation suspected of Invasive Aspergillosis

Yubhisha Dabas, India

12:29

PP1.043 - Invasive Aspergillosis: Performance of New and Established Diagnostic Approaches with Same-Day Blood and Bronchoalveolar Lavage -- a Prospective Cohort Study

Sven Heldt, Austria

12:36

PP1.044 - Clinical features and outcome of Chronic Pulmonary Aspergillosis: experience from a high tuberculosis burden country

Nousheen Iqbal, Pakistan

12:43

PP1.045 - In vivo analysis of A. fumigatus sulphur-related transcriptome during infection using a NanoString nCounter Plattform

Monica Sueiro-Olivares, United Kingdom

12:50

PP1.046 - Ultrastructural changes of Trichophyton rubrum in tinea unguium after itraconazole therapy in vivo observed using scanning electron microscopy

Aiping Wang, China

12:57

PP1.047 - Pleurotus sajor-caju can be used to synthesize silver nanoparticles with anti-fungal activity against Candida albicans

Doblin Sandai, Malaysia

13:04

PP1.048 - The presence of Candida albicans promotes Proteus mirabilis damage to enterocytes

Ilse Jacobsen, Germany

Poster Terminal 4

12:15

PP1.081 - Therapeutic effects of an antibody-derived peptide and its alanine scanning derivatives in a Galleria mellonella model of systemic candidiasis

Elisa Borghi, Italy

12:22

PP1.082 - Understanding the role of biofilms in recurrent vulvovaginal candidiasis (RVVC) and their impact on therapy

Ryan Kean, United Kingdom

12:29

PP1.083 - Major transcriptional modulations in S. aureus induced by the C. albicans secreted quorum sensing molecule farnesol

Vila Taissa, USA

12:36

PP1.084 - Distribution, Characterization and Antifungal susceptibility pattern of Candida Species in various Clinical samples at a Multispecialty Hospital – Indian scenario

Swati Salila, India

12:43

PP1.085 - Protein kinase A governs growth and virulence in Candida tropicalis

Chi-Jan Lin, Taiwan

12:50

PP1.087 - Comparative genomics of Aspergillus fumigatus and the role of agricultural azoles on the emergence of resistance

Amelia Barber, Germany

12:57

PP1.088 - In vitro antifungal susceptibility testing of Candida isolates from women with recurrent vulvovaginal candidiasis

Drosos Karageorgopoulos, Greece

Poster Terminal 5

12:15

PP1.121- Validation of diagnostic criteria for chronic pulmonary aspergillosis (CPA)

Iain Page, United Kingdom

12:22

PP1.122 - Cutaneotrichosporon (Cryptococcus) cyanovorans, a basidiomycetous yeast, described for the first time from the airways of cystic fibrosis patients

Tjomme Van der Bruggen, the Netherlands

12:29

PP1.123 - Prevalence, identification and antifungal susceptibility pattern of Candida species isolated from Iranian HIV patients with oropharyngeal candidiasis

M. Roudbary, Iran

12:36

PP1.124 - The prevalence and diversity of fungi in respiratory samples of cystic fibrosis patients – a Dutch, nationwide, prospective, multicentre study

Tobias Engel, the Netherlands

12:43

PP1.125 - Identification of encapsulated viable Cryptococcus neoformans in bronchoalveolar lavage of the patient with active pulmonary Tuberculosis and relapsing pneumonia

S. Amani Ghayoum, Iran

12:50

PP1.126 - Meta-analysis of published molecular epidemiology data of the Cryptococcus neoformans and C. gattii species complexes using the ISHAM MLST consensus

L. Trilles, Brazil

12:57

PP1.127 - Antifungal susceptibility of Cryptococcus neoformans/gattii spp complex; Comparison between clinical and environmental isolates

Nagarathna Siddaiah, India

13:04

PP1.128 - Interaction of Brazilian Clinical strains of Cryptococcus spp with macrophages

Patricia Albuquerque, Brazil

Poster Terminal 6

12:15

PP1.161 - A singular case of eumycetoma of right leg due to exophiala jeanselmi

Henry Harak, Italy

12:22

PP1.162 - Paracoccidioides antiadhesive peptide shows potential as a broad-spectrum agent against different fungi

Haroldo Cesar De Oliveira, Brazil

12:29

PP1.163 - Phenotyfipication and genotypification of Colombian clinical isolates of Sporothrix spp from the medical mycology laboratory Universidad de Antiquia, Medellin, Colombia

Laura Carolina Alvarez Acevedo, Colombia

12:36

PP1.164 - Comparative study of lipid composition of the mycelial cell wall from environmental and clinical isolates of Histoplasma capsulatum

Araque Pedronel, Colombia

12:43

PP1.165 - Outbreak of zoonotic sporotrichosis in Southern Brazil

Vanice Poester, Brazil

12:50

PP1.166 - Macrophage activation by IFN-? triggers restriction of phagosomal copper from intracellular pathogens

Qian Shen, USA

12:57

PP1.167 - Imaging mass spectrometry and microbial metabolomics on track of infectious diseases

Anton Skriba, Czech Republic

13:04

PP1.168 - Unravelling the mechanistic basis of methionine synthase essentiality

Jorge Amich, United Kingdom

Poster Terminal 8

12:15

PP1.201 - Prevalence of endobacterial symbiosis in Rhizopus microsporus (Tempe fungus)

Mohammad Javad Najafzadeh, Iran

12:22

PP1.202 - Development of the first commercial real-time PCR assay for the detection of Mucorales species

Giel Gaajetaan, the Netherlands

12:29

PP1.203 - The role of surface proteins in the virulence of Lichthemia corymbifera with alveolar macrophages

Mohamed Ismail Abdelwahab Hassan, Germany

12:36

PP1.204 - Mucormycete virulence and efficiency of posaconazole prophylaxis depends on the underlying disease

Günter Rambach, Austria

12:43

PP1.205 - Lichtheimia corymbifera: elucidating the mechanisms for iron acquisition and transport during infection

Felicia Adelina Stanford, Germany

12:50

PP1.206 - Multi-center study of Mucorales and other mould contamination of freshly-laundered linens arriving at U.S. healthcare facilities

Hong Nguyen, USA

12:57

PP1.207 - Heterogeneity and within-host adaption observed in clinical isolates of Aspergillus fumigatus

Ivan Valdes, the Netherlands

13:04

PP1.208 - Simple, low-cost micro-culture method for rapid diagnosis of mucormycosis in murine model

Hamid Badali, Iran

Sunday 01 Jul

Poster Pitch session II

Poster Terminal 1

18:00

PP2.009 - Study the effect of honey ingestion on recognition of Aspergillus fumigatus conidia by peritoneal macrophages

Donya Nikaein, Iran

18:07

PP2.010 - Occurrence of pathogenic Aspergillus species in drinking water from restaurants in Kathmandu, Nepal

Ushana Shrestha Khwakhali, Nepal

18:04

PP2.011 - Transcriptomic analysis of non –invasive infections by Aspergillus fumigatus: the case of sino-nasal aspergillosis (SNA) in dogs

Ivan Valdes, the Netherlands

18:21

PP2.012 - In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions

Hamed Fakhim, Iran

18:28

PP2.013 - Synergistic combinations of glabridin and voriconazole to battle against Aspergillus fumigatus

Mojtaba Nabili, Iran

18:35

PP2.014 - Molecular characterizations and in vitro susceptibility patterns of Aspergillus fumigatus in a tertiary care hospital, 1999–2016

Weida Liu, China

18:42

PP2.015 - Mucormycosis in Iran: a six-year retrospective experience

Ali Rezaei-Matehkolaei, Iran

18:49

PP2.016 - Volatile sulphur compounds produced by Pseudomonas aeruginosa synergize with Aspergillus fumigatus in vivo enhancing the pathobiology of co-infection

Jorge Amich, United Kingdom

Poster Terminal 2

18:00

PP2.049 - Involvement of iron metabolism in fluconazole susceptibility in Saccharomyces cerevisiae and Candida species

Liesbeth Demuyser, Belgium

18:07

PP2.050 - Cellular apoptosis: an alternative mechanism of action of caspofungin in Candida glabrata

Maryam Moazeni, Iran

18:14

PP2.051 - The Newly Characterization of a Candida albicans Isolate from a recurrent Cervical Lymphadenitis Patient and its Clinic Indication

Changzhen Zang, China

18:21

PP2.052 - Epitope unmasking in vulvovaginal candidiasis is associated with hyphal growth and neutrophilic infiltration

Eva Pericolini, Italy

18:28

PP2.053 - Candida glabrata epithelial cell damage

Marina Pekmezovic, Germany

18:35

PP2.054 - Novel formulated nanocomposite containing Indolicidin and Graphene Oxide against Candida albicans: in vitro and in vivo study

M. Roudbary, Iran

18:42

PP2.055 - Transmission-frequency of Aspergillus fumigatus in cystic fibrosis patients through coughing

Tobias Engel, the Netherlands

Poster Terminal 4

18:00

PP2.089 - Farnesol, tyrosol, and oxidative stress modulate the extracellular vesicle proteome and transcriptome in Candida albicans

Rosana Puccia, Brazil

18:07

PP2.090 - Inhibitory Effects of Lactobacillus Culture Supernatants on Candida albicans

Yuko Matsuda, Japan

18:14

PP2.091 - SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.

Stephen Barat, USA

18:21

PP2.092 - Upregulation Gene Expression Levels of SAP 1-3 Vaginal Discharge Candida albicans in Comparison to Culture of Candida albicans Isolates

Seyedmahdi Hosseini, Iran

18:28

PP2.093 - Virulence factors and susceptibility pattern of Candida albicans, Candida tropicalis and Candida glabrata from clinical specimens, Mwanza-Tanzania

Martha Mushi, Tanzania

18:35

PP2.094 - Stress-contingent changes in Candida albicans SAPK pathway architecture and regulation

Alison Day, United Kingdom

18:42

PP2.095 - Differential response of the bronchial epithelium and macrophages to Aspergillus fumigatus allergens

Sara Gogo, United Kingdom

18:49

PP2.096 - Essential requirements for Candida albicans mediated damage of epithelial cells

Selene Mogavero, Germany

Poster Terminal 5

18:00

PP2.129 - Natural habitats of Cryptococcus neoformans and C gattii in the Caribbean

Harish Gugnani, India

18:07

PP2.130 - Clinico-microbiological profile of Cryptococcal infections in non-HIV infected patients

Rungmei Marak, India

18:14

PP2.131 - The Effect of Novel Heterocyclic Compounds on Cryptococcal Biofilm

Maya Korem, Israel

18:21

PP2.132 - Inflammasome modulation by Cryptococcus neoformans extracelular vesicles produced in different conditions

Clara Luna Freitas Marina, Brazil

18:28

PP2.133 - Antifungal activity of scorpions’ venom-derived antimicrobial peptides against clinical isolates of Cryptococcus neoformans

Fernanda Guilhelmelli Costa, Brazil

18:35

PP2.134 - Immunomodulatory effects of a scorpion-venom derived antimicrobial peptide during the interaction of Cryptococcus neoformans with murine macrophages and dendritic cells

Calliandra De-Souza-Silva, Brazil

18:42

PP2.135 - Inducing pathogenicity of naive environmental C. neoformans var. grubii isolates

Hai Trieu Phan, Vietnam

18:49

PP2.136 - Phylogenetic analyses and B-cell epitope mapping of virulence factors of C. neoformans and C. gattii: An in-silico insight

Karuna Singh, India

Poster Terminal 6

18:00

PP2.169 - Cell wall robustness maintained under antibiotic stress by balanced synthesis of glucan and chitin

Jehan Abdel-moneim Abdelaziz, United Kingdom

18:07

PP2.170 - Fruits are Vehicles of Drug Resistant Pathogenic Yeasts

Hsiu-Jung Lo, Taiwan

18:14

PP2.171 - Diagnosis of invasive fungal infections through detection of a circulating pan fungal disaccharide by mass spectrometry. A european multicenter study

Daniel Poulain, France

18:21

PP2.172 - Omics approaches give new insights into genome variability and evolution of basal human pathogens of the order Mucorales

Volker Schwartze, Germany

18:28

PP2.173 - Extracellular vesicles in the black yeast Exophiala dermatitidis: a first characterization

Barbara Blasi, Vienna

18:35

PP2.174 - Transposable elements contribute to fungal genes and impact fungal lifestyle

Anna Muszewska, Poland

18:42

PP2.175 - Combining a whole blood infection assay with biomathematical modeling to classify innate immune function

Ines Leonhardt, Germany

18:49

PP2.176 - Determining the chemical composition and antifungal activities of aromatic water of Trachyspermum ammi

Kamiar Zomorodian, Iran

Poster Terminal 8

18:00

PP2.209 - Bioluminescent Mucor circinelloides – a promising new tool to study mucormycosis and antifungal drug efficacy

Ulrike Binder, Austria

18:07

PP2.210 - Molecular diagnosis of invasive aspergillosis in a child with clinical suspicion of mucormycosis

Raquel Sabino, Portugal

18:14

PP2.211 - Antifungal susceptibility patterns of rare yeasts

Antonio Pérez Hansen, Austria

18:21

PP2.212 - Impact of the use of biomarkers on early discontinuation of emirical antifungal therapy in critically ill patients: a randomised controlled study

Anahita Rouzé, France

18:28

PP2.213 - Nanoantimicrobials: A critique on Susceptibility, Mechanism of action and Toxicity on opportunistic fungal pathogens

18:35

PP2.214 - Repurposing FDA-approved Ebselen and Auranofin as anti-fungal drugs: teaching old drugs new tricks

Ashok Chaturvedi, USA

18:42

PP2.215 - Impedance-based de-replication of antifungal drug classes

Jurgen Wuyts, Belgium

18:49

PP2.216 - New Antifungal Lipopeptides from Wild- type Bacillus subtilis RLID 12.1

Ramya Ramachandran, India